//
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure
Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure
Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study
SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials
Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification
Nitrosative stress drives heart failure with preserved ejection fraction